Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Scurvy and vitamin C deficiency states].

Annales de la nutrition et de l'alimentation·2014
Same author

Value of transrectal power Doppler sonography in the detection of low-risk prostate cancers.

Diagnostic and interventional imaging·2012
Same author

Notes on the Center's polio epidemic in 1943.

Archives francaises de pediatrie·2010
Same author

Purulent streptococcal peritonitis of a newborn born with sulfonamidotherapy.

Archives francaises de pediatrie·2010
Same authorSame journal

Osteomyelitis with acute staphylococcus aureus with septicemia and pericarditis cured without surgery by iodo-sulfonamide therapy.

Archives francaises de pediatrie·2010
Same authorSame journal

Intermittent jaundice; intrahepatic bile duct agenesis.

Archives francaises de pediatrie·2010
Same journal

A case of congenital myatonia (Oppenheim's disease).

Archives francaises de pediatrie·2010
Same journal

A case of severe haemolytic anemia anemia.

Archives francaises de pediatrie·2010
Same journal

On the acute anemia of the newborn.

Archives francaises de pediatrie·2010
Same journal

Mickulicz syndrome and hepatomegaly during a diabetes mellitus.

Archives francaises de pediatrie·2010
See all related articles

Related Experiment Video

Updated: Jun 7, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)

Published on: February 9, 2011

Sulfamidotherapy in pediatrics

P ROHMER, R SACREZ

    Archives Francaises De Pediatrie
    |October 29, 2010
    PubMed
    Summary

    No abstract available in PubMed .

    Keywords:
    SULFONAMIDES/therapy--in pediatrics

    Related Experiment Videos

    Last Updated: Jun 7, 2026

    Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
    12:18

    Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)

    Published on: February 9, 2011